Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986207 + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986207 + nivolumab + ipilimumab is a combination of three monoclonal antibodies developed for the treatment of advanced solid tumors and stage IV non-small cell lung cancer (NSCLC). BMS-986207 is a novel anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) monoclonal antibody, nivolumab is an anti–PD-1 (programmed death-1) immune checkpoint inhibitor, and ipilimumab is an anti–CTLA-4 (cytotoxic T-lymphocyte–associated antigen 4) antibody. Together, these drugs enhance anti-tumor immune responses through complementary inhibition of immune checkpoints, which regulate T-cell activation and longevity. Clinical trials have studied this combination as a first-line therapy in NSCLC and in advanced solid tumors[1][2][3][5][6][7][8][9][10].
- Other names
- BMS-986207 + Opdivo + Yervoy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on BMS-986207 + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986207 + nivolumab + ipilimumab.